Interferon beta-1a in children with multiple sclerosis is well tolerated

Neuropediatrics. 2001 Aug;32(4):211-3. doi: 10.1055/s-2001-17370.


Background: Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults.

Objective: To determine the tolerability of interferon beta-1a (IFNB-1 a) 30 mcg injected intramuscularly once a week in children with clinically definite relapsing-remitting multiple sclerosis (RRMS).

Design/methods: A standardized questionnaire was sent to neurologists in the United States to determine the tolerability of IFNB-1 a in patients younger than 16 years.

Results: Tolerability data were available for 9 of 33 children who were reported to initiate IFNB-1 a. Mean age on initiating treatment was 12.7 years (range 8 - 15) and mean duration of therapy was 17 months (range 5 - 36). No patient discontinued therapy due to an adverse event.

Conclusions: Preliminary data indicate that weekly intramuscular injections of IFNB-1 a are well tolerated.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adolescent
  • Child
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Interferon beta-1a
  • Interferon-beta / administration & dosage*
  • Interferon-beta / adverse effects
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Patient Compliance
  • Retrospective Studies
  • Treatment Outcome


  • Adjuvants, Immunologic
  • Interferon-beta
  • Interferon beta-1a